<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211121053131N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-18</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of effectiveness of two types of suture during intraoral incisions healing</public_title>
      <acronym>-</acronym>
      <scientific_title>Comparison of effectiveness of Simple continuous suture and Reciprocal continuous suture in healing intraoral incisions: double blind, split mouth randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>14</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60171</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study there are 4 randomized interventions. Right side first or left side, and each one is first can be sutured either with Reciprocal continuous suture or Simple continuous suture.

1) Right side first, suturing with Reciprocal continuous technique.
2) Right side first, suturing with Simple continuous technique.
3) Left side first, suturing with Reciprocal continuous technique.
4) Left side first, suturing with Simple continuous technique.

There are 14 patients in this study. In this method we write down these 4 interventions in 4 similar sealed envelopes (there is 1 intervention in each envelope). For each 4 patients we have 4 envelopes, for first patient we choose one envelope randomly. For second patient we choose one envelope from 3 remaining envelopes and so on until the last patient. In the end this process will be done 3 times for 12 patients. For 2 remaining patients we have 2 new envelopes that are sealed and similar. In each 2 envelopes we write one of the interventions, it means that for each intervention we have a separate envelope. This method is called Balanced Block Randomization, Blinding description: Patients do not know which type of suture is performed on which side of the maxilla. With Balanced Block Randomization method surgeon will decide to do which suture technique on each side. Also impact assessor does not know which type of suture is performed on which side of the maxilla because he evaluates the photographs that is taken after suture removal.</study_design>
      <phase>N/A</phase>
      <hc_freetext>This study evaluates the effectiveness of a new suturing technique that has been invented by researcher. This technique name is Reciprocal continuous suture which is a type of continuous suture..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The side of Maxilla that receives Reciprocal continuous suture is intervention group. First, each side of the Maxilla is anesthetized with approximately 2 carpules of Lidocaine anesthetic and infiltration technique. With a razor number 15 (Morris Company), the Crestal incision is done, envelope flap is prepared and the flap is retracted mucoperioceally. The most posterior region of the maxilla where the implant is placed is first maxillary molar. One implant system is used for all patients and all implants are placed with 2 stage technique. After implant placement, one side of the maxilla is sutured with Simple continuous suture technique (control group) and the opposite side is sutured with the Reciprocal continuous suture technique (intervention group). The suturing process on each side is completely random (Balanced Block Randomization method) and it means that the surgeon didn’t apply his personal opinion for suturing (which side first and which suturing technique first). The point where the needle enters the tissue is far 3 mm from the edge of the wound. The surgical site is sutured with 0.3 Vikril absorbable (slowly absorb) suture (brand name: SUPABON made in Iran / SUPA company) with a 19 mm reverse cutting needle and a 3.8 gauge. Both side sutures will be remove 7 days after surgery. On surgery day, 7 days and 14 days after surgery intraoral photograph is taken. In the end intraoral photographs will be evaluate by impact assessor with AutoCAD software. Intervention 2: Control group: The side of Maxilla that receives Simple continuous suture is control group. First, each side of the Maxilla is anesthetized with approximately 2 carpules of Lidocaine anesthetic and infiltration technique. With a razor number 15 (Morris Company), the Crestal incision is done, envelope flap is prepared and the flap is retracted mucoperioceally. The most posterior region of the maxilla where the implant is placed is first maxillary molar. One implant system is used for all patients and all implants are placed with 2 stage technique. After implant placement, one side of the maxilla is sutured with Simple continuous suture technique (control group) and the opposite side is sutured with the Reciprocal continuous suture technique (intervention group). The suturing process on each side is completely random (Balanced Block Randomization method) and it means that the surgeon didn’t apply his personal opinion for suturing (which side first and which suturing technique first). The point where the needle enters the tissue is far 3 mm from the edge of the wound. The surgical site is sutured with 0.3 Vikril absorbable (slowly absorb) suture (brand name: SUPABON made in Iran / SUPA company) with a 19 mm reverse cutting needle and a 3.8 gauge. Both side sutures will be remove 7 days after surgery. On surgery day, 7 days and 14 days after surgery intraoral photograph is taken. In the end intraoral photographs will be evaluate by impact assessor with AutoCAD software.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Because the participants have not been determined yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Houra Astaneh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 4, Habibi Rad alley, Qoba street, Shariati avenue, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1948934511</zip>
        <telephone>+98 21 2284 9948</telephone>
        <email>huas74@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nima Dehghani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran University of Medical Sciences, International Campus, School of Dentistry  Mahan St., Zam Zam St., Navab Highway, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1894787545</zip>
        <telephone>00982155851131, 55851141, 55851149</telephone>
        <email>dentistryic@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Healthy people(without systemic diseases)
People who do not smoke
Women who are not during pregnancy
Women who are not during breastfeeding
People who visit for follow-up sessions
People who do not need bone grafts for implant surgery</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with systemic disease
Smokers
Pregnant women
Women who are breastfeeding
Patients who need bone graft for implant surgery
Patients who do not seek follow-up sessions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The side of Maxilla that receives Reciprocal continuous suture is intervention group. First, each side of the Maxilla is anesthetized with approximately 2 carpules of Lidocaine anesthetic and infiltration technique. With a razor number 15 (Morris Company), the Crestal incision is done, envelope flap is prepared and the flap is retracted mucoperioceally. The most posterior region of the maxilla where the implant is placed is first maxillary molar. One implant system is used for all patients and all implants are placed with 2 stage technique. After implant placement, one side of the maxilla is sutured with Simple continuous suture technique (control group) and the opposite side is sutured with the Reciprocal continuous suture technique (intervention group). The suturing process on each side is completely random (Balanced Block Randomization method) and it means that the surgeon didn’t apply his personal opinion for suturing (which side first and which suturing technique first). The point where the needle enters the tissue is far 3 mm from the edge of the wound. The surgical site is sutured with 0.3 Vikril absorbable (slowly absorb) suture (brand name: SUPABON made in Iran / SUPA company) with a 19 mm reverse cutting needle and a 3.8 gauge. Both side sutures will be remove 7 days after surgery. On surgery day, 7 days and 14 days after surgery intraoral photograph is taken. In the end intraoral photographs will be evaluate by impact assessor with AutoCAD software.</i_keyword>
      <i_keyword>Control group: The side of Maxilla that receives Simple continuous suture is control group. First, each side of the Maxilla is anesthetized with approximately 2 carpules of Lidocaine anesthetic and infiltration technique. With a razor number 15 (Morris Company), the Crestal incision is done, envelope flap is prepared and the flap is retracted mucoperioceally. The most posterior region of the maxilla where the implant is placed is first maxillary molar. One implant system is used for all patients and all implants are placed with 2 stage technique. After implant placement, one side of the maxilla is sutured with Simple continuous suture technique (control group) and the opposite side is sutured with the Reciprocal continuous suture technique (intervention group). The suturing process on each side is completely random (Balanced Block Randomization method) and it means that the surgeon didn’t apply his personal opinion for suturing (which side first and which suturing technique first). The point where the needle enters the tissue is far 3 mm from the edge of the wound. The surgical site is sutured with 0.3 Vikril absorbable (slowly absorb) suture (brand name: SUPABON made in Iran / SUPA company) with a 19 mm reverse cutting needle and a 3.8 gauge. Both side sutures will be remove 7 days after surgery. On surgery day, 7 days and 14 days after surgery intraoral photograph is taken. In the end intraoral photographs will be evaluate by impact assessor with AutoCAD software.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Dehiscence: Pathologic process consisting of a partial or complete disruption of the layers of a surgical wound. Timepoint: 7 days and 14 days after surgery. Method of measurement: Intraoral measuring instruments (graded bisturi handle - mm).</prim_outcome>
      <prim_outcome>Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Timepoint: 7 days and 14 days after surgery. Method of measurement: Pale pink: without inflammation, change in color from normal pale pink: inflammation.</prim_outcome>
      <prim_outcome>Suturing loosening. Timepoint: 7 days after surgery. Method of measurement: Intraoral measuring instruments (graded bisturi handle - mm).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-07-29</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Tehran university of medical sciences international campus school of dentistry, Mahan St., Zam Zam St., Navab Highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
